Loading
A phase 1 trial of LB2102 in extensive-stage small-cell lung cancer and large cell neuroendocrine carcinoma of the lung, run by Legend Biotech USA Inc, active but no longer recruiting.
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer is a phase 1 interventional study registered as NCT05680922 by Legend Biotech USA Inc; 41 participants are planned, it started on 2023-07-26; the registry gives 2027-12 as its primary completion date. Interventions recorded: LB2102. Conditions listed: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung. No results are recorded here; the registry entry is the source.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/